Development of a novel tyrosine kinase 2 inhibitor ARTS‐011 and its first‐in‐human single and multiple ascending dose Phase I study to evaluate the tolerability, safety, pharmacokinetic profile and food effects

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Zhili Jin, Jingxuan Wu, Jiaqi Liang, Jing Yang, Qing Sheng, Zhen Liu, Yan Wang, Cong Zhu, Xipan Liu, Wenheng Liang, Xiaobin Zhang, Yaoyu Chen, Jiangshuo Li, Yuqin Song, Xiaofang Wu, Jingcheng Chen, Tao Ji, Ruihua Dong
Formato:	Artículo Open Access
Publicado:	Wiley 2026
Materias:	British Journal of Pharmacology
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Pharmacology and safety of TAS5315, a Bruton tyrosine kinase inhibitor, in healthy volunteers: First‐in‐human, randomized, ascending‐dose studies
por: Yuji Kumagai, et al.
Publicado: (2025)

Evaluation of drug–drug interactions of a novel potent FLT3 inhibitor SKLB1028 in healthy subjects
por: Jingcheng Chen, et al.
Publicado: (2024)

Single‐ascending dose and food effect studies to assess safety and pharmacokinetics of ainuovirine, a novel non‐nucleoside reverse transcriptase inhibitor, for treatment of HIV‐1 infection
Publicado: (2024)

Efficacy, tolerability, and safety of Efsubaglutide Alfa in participants with obesity or overweight ( LIGHT 1): A randomized, double‐blind, placebo‐controlled, ascending‐dose phase 2a trial
por: Fei Gao, et al.
Publicado: (2026)

Safety, tolerability, pharmacokinetics and pharmacodynamics of HSK31858, a novel oral dipeptidyl peptidase‐1 inhibitor, in healthy volunteers: An integrated phase 1, randomized, double‐blind, placebo‐controlled, single‐ and multiple‐ascending dose study
por: Yuhao Wang, et al.
Publicado: (2025)

Washed microbiota transplantation alleviates tyrosine kinase inhibitors associated gastrointestinal adverse effects
por: Weihong Wang, et al.
Publicado: (2025)

Phenotype versus genotype to optimize cancer dosing in the clinical setting—focus on 5‐fluorouracil and tyrosine kinase inhibitors
por: Jennifer H. Martin, et al.
Publicado: (2024)

Randomized, double‐blind, phase 1a single‐ascending dose and food effect studies assessing safety and pharmacokinetics of EC5026 in healthy volunteers
por: William K. Schmidt, et al.
Publicado: (2024)

Translational modelling to predict human pharmacokinetics and pharmacodynamics of a Bruton's tyrosine kinase‐targeted protein degrader BGB‐16673
por: Yue Wu, et al.
Publicado: (2024)

An open‐label, multiple ascending dose trial of orally administered insulin Tregopil in patients with type 1 diabetes mellitus to evaluate its pharmacokinetics, pharmacodynamics, safety and tolerability
por: Esther Latres, et al.
Publicado: (2025)

Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies
por: Xuejin Ou, et al.
Publicado: (2024)

Molecular basis for differential recognition of an allosteric inhibitor by receptor tyrosine kinases
por: Jyoti Verma, et al.
Publicado: (2024)

Efficacy, safety and predictive biomarker of third‐generation tyrosine kinase inhibitors with azacitidine in myeloid blast phase of chronic myeloid leukemia
por: Mei Bao, et al.
Publicado: (2025)

Covalent Bruton tyrosine kinase inhibitors across generations: A focus on zanubrutinib
por: Alessandro Broccoli, et al.
Publicado: (2025)

Outcomes of pregnancy in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors
por: Takeshi Kondo, et al.
Publicado: (2024)

Safety, tolerability, and pharmacokinetics of single and multiple ascending doses of zavegepant nasal spray in healthy adults from two phase 1 randomized, placebo‐controlled trials
por: Richard Bertz, et al.
Publicado: (2025)

Safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of HRS‐1893, a cardiac myosin inhibitor, in healthy subjects
por: Kexu Yang, et al.
Publicado: (2026)

Treatment‐free remission in chronic myeloid leukaemia patients with accelerated phase or tyrosine kinase inhibitor therapy failure
por: Mengyao Yuan, et al.
Publicado: (2025)

Postoperative circulating tumor cells predict the benefits of tyrosine kinase inhibitor for hepatocellular carcinoma after transplantation
por: De‐Zhen Guo, et al.
Publicado: (2025)

Comprehensive analysis of body composition features in melanoma patients treated with tyrosine kinase inhibitors
por: Miriam Mengoni, et al.
Publicado: (2024)

Acute cardiotoxicity in pediatric and adolescent patients with solid tumors treated with tyrosine kinase inhibitors
por: Jessica Gartrell, et al.
Publicado: (2025)

Leg ulcers associated with tyrosine kinase inhibitors of vascular endothelial growth factor receptors
por: Lykimheng Lor, et al.
Publicado: (2025)

Safety, tolerability and pharmacokinetics of DNDI‐6148, a novel agent for leishmaniasis: A randomized, controlled, single ascending dose study in healthy participants
por: Jean‐Yves Gillon, et al.
Publicado: (2025)

Safety, tolerability, and pharmacokinetics of single‐ and multiple‐ascending doses of olamkicept: Results from randomized, placebo‐controlled, first‐in‐human phase I trials
por: Frank‐Dietrich Wagner, et al.
Publicado: (2024)

Bruton's tyrosine kinase inhibition suppresses pathological retinal angiogenesis
por: Siyue Chen, et al.
Publicado: (2024)

Maintenance therapy with the FMS‐like tyrosine kinase 3 inhibitor gilteritinib in patients with FMS‐like tyrosine kinase 3–internal tandem duplication acute myeloid leukemia: A phase 2 study
por: Emmanuel Gyan, et al.
Publicado: (2025)

Revolutionizing non‐melanoma skin cancer treatment: Receptor tyrosine kinase inhibitors take the stage
por: Nasim Gholizadeh, et al.
Publicado: (2024)

Hand–foot skin reaction as a positive prognostic factor in vascular endothelial growth factor receptor‐tyrosine kinase inhibitor treatment
por: I‐Hsin Huang, et al.
Publicado: (2026)

The safety, tolerability, pharmacokinetics and pharmacodynamics of GZR18 in healthy American and Chinese adult subjects
por: Yue Liu, et al.
Publicado: (2025)

Outcomes of Bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia in US veterans with severe renal dysfunction
por: Chenyu Lin, et al.
Publicado: (2024)

Unveiling the nephrotoxic profile of BCR‐ABL tyrosine kinase inhibitors: A real‐world experience in Africa
por: Zekarias Seifu Ayalew, et al.
Publicado: (2024)

First‐in‐human safety, tolerability, pharmacokinetics and pilot food‐effect study of the candidate antimalarial compound MMV367
por: Andrea Kuemmerle, et al.
Publicado: (2025)

A randomized, double‐blind, placebo‐controlled, multiple ascending dose study to evaluate the efficacy, pharmacokinetics, and safety of ABBV‐916 in adults with early Alzheimer’s disease
por: Shau Yu Lynch, et al.
Publicado: (2025)

The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of mitiperstat
por: Chandrali S. Bhattacharya, et al.
Publicado: (2024)

Targeting STAT3, FOXO3a, and Pim‐1 kinase by FDA‐approved tyrosine kinase inhibitor–Radotinib: An in silico and in vitro approach
por: Suryaa Manoharan, et al.
Publicado: (2024)

Pharmacokinetics, pharmacodynamics, and safety of izuforant, an H4R inhibitor, in healthy subjects: A phase I single and multiple ascending dose study
por: Byung Hak Jin, et al.
Publicado: (2024)

A Double‐Blind, Placebo‐Controlled, Single‐Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT‐101, an RNAi Therapeutic Targeting HBV Infection
por: Jianxiong Zhang, et al.
Publicado: (2025)

Comparative efficacy of receptor tyrosine kinase inhibitors in a mouse model of alkali burn‐induced corneal neovascularization
por: Titas Gladkauskas, et al.
Publicado: (2025)

In vitro PK/PD modeling of tyrosine kinase inhibitors in non‐small cell lung cancer cell lines
por: Linda Wanika, et al.
Publicado: (2024)

Comparative efficacy of receptor tyrosine kinase inhibitors in a mouse model of alkali burn‐induced corneal neovascularization
por: Titas Gladkauskas, et al.
Publicado: (2025)